WO2025068949 - EMRUSOLMIN FOR USE IN TREATING MULTIPLE SYSTEM ATROPHY
National phase entry:
Publication Number
WO/2025/068949
Publication Date
03.04.2025
International Application No.
PCT/IB2024/059428
International Filing Date
26.09.2024
Title **
[English]
EMRUSOLMIN FOR USE IN TREATING MULTIPLE SYSTEM ATROPHY
[French]
EMRUSOLMINE DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT D'UNE ATROPHIE MULTISYSTÉMATISÉE
Applicants **
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Inventors
GIESE, Armin
LEVIN, Johannes
IZGELOV, Dvora
PERLSTEIN, Itay
CHEN, Maria
KNEBEL, Helena
SINGH, Rajendra Pratap
GROSSMAN, Moran
MAGID, Lital
RUBINSTEIN, Efrat
AHN, Andrew
BARASH, Steve
CICALI, Brian
SCHMIDT, Stephan
Priority Data
63/585,458
26.09.2023
US
63/683,752
16.08.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2705 | |
| EPO | Filing, Examination, Granting | 10702 | |
| Japan | Filing, Examination, Granting | 2124 | |
| South Korea | Filing, Examination, Granting | 2042 | |
| USA | Filing, Examination, Granting | 5190 |
Total:
22,763
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The disclosure provides methods of stabilizing one or more symptoms of Multiple System Atrophy (MSA), limiting the clinical progression of MSA, slowing the clinical progression of MSA, o stabilizing the clinical progression of MSA in a human or population of humans in need thereof, comprising orally administering, on a daily basis, of 300 mg emrusolmin to the human or humans. The disclosure also provide methods of improving overall survival in a human with MSA, improving progress-free survival in a human with MSA, or treating a human having Multiple System Atrophy (MSA) and in need of treatment thereof, comprising orally administering about 300 mg of emrusolmin to the human.[French]
La divulgation concerne des procédés de stabilisation d'un ou de plusieurs symptômes de l'atrophie multisystématisée (AMS), limitant la progression clinique de l'AMS, ralentissant la progression clinique de l'AMS, o stabilisant la progression clinique de l'AMS chez un être humain ou une population d'êtres humains en ayant besoin, comprenant l'administration par voie orale, sur une base quotidienne, de 300 mg d'emrusolmine à l'être humain ou à l'homme. La divulgation concerne également des procédés d'amélioration de la survie globale chez un être humain atteint de l'AMS, d'amélioration de la survie sans progression chez un être humain atteint de l'AMS, ou de traitement d'un être humain ayant une atrophie multisystématisée (MSA) et nécessitant un traitement de celui-ci, comprenant l'administration par voie orale d'environ 300 mg d'emrusolmine à l'être humain.